NASDAQ:AXSM Axsome Therapeutics (AXSM) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free AXSM Stock Alerts $72.54 -3.00 (-3.97%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$72.21▼$75.8050-Day Range$69.39▼$97.6452-Week Range$55.02▼$98.40Volume582,906 shsAverage Volume771,592 shsMarket Capitalization$3.44 billionP/E RatioN/ADividend YieldN/APrice Target$116.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Axsome Therapeutics alerts: Email Address Axsome Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside60.0% Upside$116.10 Price TargetShort InterestBearish15.77% of Shares Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.62Based on 23 Articles This WeekInsider TradingSelling Shares$2.09 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.71) to $1.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.62 out of 5 starsMedical Sector85th out of 947 stocksPharmaceutical Preparations Industry32nd out of 435 stocks 4.4 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $116.10, Axsome Therapeutics has a forecasted upside of 60.0% from its current price of $72.54.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.77% of the outstanding shares of Axsome Therapeutics have been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Axsome Therapeutics has recently decreased by 0.66%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxsome Therapeutics has received a 69.39% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.Environmental SustainabilityThe Environmental Impact score for Axsome Therapeutics is -1.03. Previous Next 2.0 News and Social Media Coverage News SentimentAxsome Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Axsome Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 18 people have searched for AXSM on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 20 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,089,327.00 in company stock.Percentage Held by Insiders24.50% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.60% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($3.71) to $1.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -13.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -13.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 17.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Axsome Therapeutics Stock (NASDAQ:AXSM)Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Read More AXSM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXSM Stock News HeadlinesMarch 16, 2024 | insidertrades.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Director Roger Jeffs Sells 29,976 SharesMarch 18, 2024 | americanbankingnews.comInsider Selling: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Sells $2,089,327.20 in StockMarch 19, 2024 | Porter & Company (Ad)The world’s greatest investmentI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.March 17, 2024 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Shares Up 6.1%March 17, 2024 | finance.yahoo.comAXSM Apr 2024 120.000 callMarch 17, 2024 | finance.yahoo.comAXSM Apr 2024 87.500 putMarch 16, 2024 | finance.yahoo.comAXSM Apr 2024 87.500 callMarch 16, 2024 | finance.yahoo.comAXSM Apr 2024 92.500 putMarch 19, 2024 | Porter & Company (Ad)The world’s greatest investmentI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.March 16, 2024 | finance.yahoo.comAXSM Apr 2024 72.500 callMarch 16, 2024 | finance.yahoo.comAXSM Apr 2024 50.000 putMarch 15, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for Axsome Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:AXSM)March 15, 2024 | finance.yahoo.comAXSM May 2024 80.000 callMarch 14, 2024 | americanbankingnews.comAxsome Therapeutics, Inc. Expected to Post FY2026 Earnings of $2.86 Per Share (NASDAQ:AXSM)March 5, 2024 | markets.businessinsider.comAxsome Therapeutics Maintains Buy Rating Amid Temporary DisruptionMarch 5, 2024 | finance.yahoo.comAXSM Apr 2024 70.000 callMarch 5, 2024 | globenewswire.comAxsome Therapeutics to Present at the Leerink Partners Global Biopharma ConferenceFebruary 27, 2024 | markets.businessinsider.comWhat Analysts Are Saying About Axsome Therapeutics StockFebruary 27, 2024 | globenewswire.comAxsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceFebruary 26, 2024 | investorplace.com3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024February 26, 2024 | fool.com3 Biotech Stocks to Buy and Hold for the Next 10 YearsFebruary 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Axsome Therapeutics Amid Strong Financials and Promising PipelineFebruary 21, 2024 | finance.yahoo.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2023 Earnings Call TranscriptFebruary 21, 2024 | finance.yahoo.comAxsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue BeatFebruary 21, 2024 | seekingalpha.comAxsome: Unpacking Auvelity's First-Year Market Dynamics And Economic ChallengesFebruary 20, 2024 | finance.yahoo.comQ4 2023 Axsome Therapeutics Inc Earnings CallFebruary 20, 2024 | msn.comAxsome Therapeutics (AXSM) Q4 2023 Earnings Call TranscriptSee More Headlines Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today3/18/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AXSM CUSIPN/A CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees545Year FoundedN/APrice Target and Rating Average Stock Price Target$116.10 High Stock Price Target$180.00 Low Stock Price Target$81.00 Potential Upside/Downside+60.0%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($5.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-239,240,000.00 Net Margins-88.41% Pretax Margin-88.06% Return on Equity-70.67% Return on Assets-27.47% Debt Debt-to-Equity Ratio0.93 Current Ratio3.63 Quick Ratio3.52 Sales & Book Value Annual Sales$270.60 million Price / Sales12.70 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book17.96Miscellaneous Outstanding Shares47,370,000Free Float35,767,000Market Cap$3.44 billion OptionableOptionable Beta1.17 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Herriot Tabuteau M.D. (Age 56)Founder, Chairman, CEO & President Comp: $1.32MMr. Nick Pizzie CPA (Age 49)M.B.A., Chief Financial Officer Comp: $732.94kMr. Mark L. Jacobson (Age 41)COO & Secretary Comp: $784.66kMr. Hunter Murdock Esq. (Age 44)General Counsel & Secretary Comp: $735.39kDr. Amanda Jones Pharm.D. (Age 41)Senior Vice President of Clinical Development Ms. Lori Englebert M.B.A. (Age 46)Executive Vice President of Commercial & Business Development Joseph Debrah-Afful CPAM.B.A., Director of FinanceMore ExecutivesKey CompetitorsRayzeBioNASDAQ:RYZBCorcept TherapeuticsNASDAQ:CORTRa PharmaceuticalsNASDAQ:RARXAimmune TherapeuticsNASDAQ:AIMTGlobal Blood TherapeuticsNASDAQ:GBTView All CompetitorsInsiders & InstitutionsRoger JeffsSold 29,976 sharesTotal: $2.09 M ($69.70/share)Vanguard Group Inc.Sold 32,360 shares on 3/11/2024Ownership: 7.804%Wellington Management Group LLPBought 2,265 shares on 3/5/2024Ownership: 0.506%American International Group Inc.Bought 162 shares on 2/28/2024Ownership: 0.037%Perceptive Advisors LLCBought 556,370 shares on 2/26/2024Ownership: 2.194%View All Insider TransactionsView All Institutional Transactions AXSM Stock Analysis - Frequently Asked Questions Should I buy or sell Axsome Therapeutics stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares. View AXSM analyst ratings or view top-rated stocks. What is Axsome Therapeutics' stock price target for 2024? 11 equities research analysts have issued 12-month price targets for Axsome Therapeutics' shares. Their AXSM share price targets range from $81.00 to $180.00. On average, they anticipate the company's share price to reach $116.10 in the next year. This suggests a possible upside of 60.0% from the stock's current price. View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts. How have AXSM shares performed in 2024? Axsome Therapeutics' stock was trading at $79.59 at the beginning of the year. Since then, AXSM stock has decreased by 8.9% and is now trading at $72.54. View the best growth stocks for 2024 here. When is Axsome Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our AXSM earnings forecast. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its earnings results on Tuesday, February, 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.21) by $0.48. The business had revenue of $71.53 million for the quarter, compared to analyst estimates of $70.38 million. Axsome Therapeutics had a negative net margin of 88.41% and a negative trailing twelve-month return on equity of 70.67%. What ETFs hold Axsome Therapeutics' stock? ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What guidance has Axsome Therapeutics issued on next quarter's earnings? Axsome Therapeutics issued an update on its fourth quarter 2023 earnings guidance on Thursday, January, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $71.0 million-$71.0 million, compared to the consensus revenue estimate of $66.4 million. What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY). When did Axsome Therapeutics IPO? (AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.81%), Vanguard Group Inc. (7.80%), BVF Inc. IL (4.19%), Perceptive Advisors LLC (2.19%), Point72 Asset Management L.P. (1.77%) and Bellevue Group AG (1.34%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AXSM) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.